by Mariam Kiparoidze | Nov 27, 2023
Photo: Wikimedia Commons Covid made Pfizer a household name and sent its revenues and profits soaring. Now flush with cash and amid its post-covid slump, Pfizer is betting that its next blockbuster drug could be a cancer treatment. The pharma giant made headlines...
by Mariam Kiparoidze | Nov 3, 2023
Photo credit:Wikimedia Commons Pfizer reported a loss in the third quarter as it tries to adapt to the faltering demand on its Covid-19 drug and vaccines. Pfizer reported a net loss of $2.38 billion last quarter, missing analyst expectations, the pharmaceutical giant...
by Mariam Kiparoidze | Oct 3, 2023
Image by Mike Ramírez Mx from Pixabay Pharmaceutical giant Pfizer has teamed up with a biology biotech company Ginkgo Bioworks to research and develop RNA medicines, following a series of acquisitions and partnerships to grow and diversify its portfolio With...
by Mariam Kiparoidze | Sep 28, 2023
Even though Covid-19 cases and hospitalization numbers are up, they won’t be a shot in the arm for either Moderna or Pfizer stock. Pfizer (NYSE:PFE) closed at $32.69 per share, down by 36.2% year to date on September 22. Moderna (Nasdaq:MRNA) ended the week on a...
by Suzannah Cavanaugh | Oct 2, 2020
Moderna Inc. announced Tuesday that its Covid-19 vaccine candidate had generated levels of virus-neutralizing antibodies in older adults on par with those produced in younger trial participants, a crucial step towards approval. The early-stage result gives Moderna a...
